Cingulate Inc. (CING) News
Track canonical SquawkNews coverage tagged to CING, Cingulate Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Cingulate reports Q2 2026 results; CTx-1301 NDA resubmission update
Cingulate Inc. reports its second quarter 2026 financial results and provides an update on CTx-1301 CMC progress toward NDA resubmission and commercial readiness.
EARNINGS | Aug 13, 2026, 12:30 PM UTC
L
CINGW CING - Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology - Click For
CINGW CING - Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
EQUITY | Jul 30, 2026, 12:31 PM UTC
L
Cingulate Joins Russell 3000E Index
Cingulate Inc. (NASDAQ: CING ), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical pr
EQUITY | Jul 02, 2026, 12:30 PM UTC